(Q43777231)

26 November 2017

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer (English)

1 reference

26 November 2017

1 reference

4

J Baselga

1 reference

26 November 2017

J Bellmunt

1

1 reference

26 November 2017

R de Wit

series ordinal

2

1 reference

26 November 2017

J Albanell

series ordinal

3

1 reference

26 November 2017

1 November 2001

1 reference

European Journal of Cancer

26 November 2017

1 reference

26 November 2017

37

1 reference

26 November 2017

2212-2215

1 reference

26 November 2017

17

1 reference

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Carboplatin, Methotrexate and Vinblastin (Carbo-MV) for Advanced Urothelial Cancer A Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Carboplatin-based chemotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900295-7

7 January 2021

10.1016/S0959-8049(01)00295-7

Identifiers

DOI

1 reference

release_oobjjlof6vfkdcwdi2rayh3c4a

26 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oobjjlof6vfkdcwdi2rayh3c4a

24 November 2022

mapped directly with Wikidata item

1 reference